Ethical issues in oncology biostatistics

Statistical Methods in Medical Research

Volumn 11, Issue 5, 2002, Pages 429-448

  Thall, Peter F ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DICHLOROPHEN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; INTERFERON;

BIOSTATISTICS; BREAST CANCER; CANCER; CANCER CENTER; CANCER RADIOTHERAPY; CANCER RISK; CANCER STATISTICS; CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG TOXICITY; EXPERIENCE; HEART DISEASE; HUMAN; IMMUNOPATHOLOGY; INFORMED CONSENT; KIDNEY DISEASE; LEUKOPENIA; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL PRACTICE; MEDICAL RESEARCH; MONITORING; MOTOR DYSFUNCTION; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; ONCOLOGY; PROCESS DESIGN; PROFESSIONAL PRACTICE; PUBLISHING; QUALITY CONTROL; RANDOMIZATION; REVIEW; RISK BENEFIT ANALYSIS; SAFETY; SIDE EFFECT;

BIOMETRY; CANCER CARE FACILITIES; CLINICAL TRIALS; ETHICS; ETHICS, RESEARCH; HUMANS; INFORMED CONSENT; MEDICAL ONCOLOGY; RANDOM ALLOCATION; RESEARCH DESIGN; TEXAS; UNITED STATES;

EID: 0036783715     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1191/0962280202sm301ra     Document Type: Review

References (33)

1. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes
2. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials
3. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials
4. Decision theoretic designs for phase II clinical trials with multiple outcomes
5. Incorporating toxicity considerations into the design of two-stage phase II clinical trials
6. Designs for phase II trials allowing for a trade-off between response and toxicity
7. Hypothesis testing and sample size for bivariate binomial response in the comparison of two groups
8. Group sequential tests for bivariate response: Interim analysis of clinical trials with both efficacy and safety endpoints
9. Coupled error spending functions for parallel bivariate sequential tests
10. Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials
11. Optimal two-stage designs for clinical trials based on safety and efficacy
12. Approximate Bayesian evaluation of multiple treatment effects
13. Selecting therapeutic strategies based on efficacy and death in multi-course clinical trials
14. Incorporating utility-based quality-of-life assessment analysis
15. Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis
16. Quality adjusted survival analysis
17. A consistent estimator for the distribution of quality adjusted survival time
18. Optimal two-stage designs for phase II clinical trials
19. Ethics and statistics in randomized clinical trials
20. Progress toward a more ethical method for clinical trials
21. Investigating therapies of potentially great benefit: ECMO
22. On the likelihood that one unknown probability exceeds another in view of the evidence in two samples
23. The use of response-adaptive designs in clinical trials
24. Adaptive assignment versus balanced randomization in clinical trials: A decision analysis
25. New directions in adaptive designs
26. Accrual strategies for phase I trials with delayed patient outcome
27. Sequential designs for phase I clinical trials with late-onset toxicities
28. The two-armed bandit with delayed responses
29. Monitoring the rates of composite events with censored data in phase II clinical trials
30. Toward an informed discussion of informed consent